ETF Industry News - The three major indices collectively rose, with the Shanghai Composite Index up 0.43%, the Shenzhen Component Index up 0.65%, and the ChiNext Index up 1.07. Multiple innovative drug ETFs saw significant gains, including Tianhong Innovative Drug ETF (517380.SH) up 4.36%, Fortune Innovative Drug ETF (159748.SZ) up 3.57%, and Guotai Innovative Drug ETF (517110.SH) up 3.13% [1] - The bond ETF market has reached a significant milestone, surpassing 300 billion yuan in total scale, following the earlier milestone of 200 billion yuan in February. Notably, several bond ETFs have exceeded 48 billion yuan in scale, indicating structural growth in the bond ETF market [2] - A new wave of fund fee reductions has been implemented, with nearly 10 funds from various companies announcing fee cuts, primarily in bond products. This trend is expected to lower investment costs for investors [3] - The issuance of equity funds has seen a resurgence, with four new equity funds raising over 1 billion yuan since June, indicating a shift of funds towards high-performing funds and favored fund managers [4] Market Performance Overview - The overall performance of ETFs shows that cross-border ETFs had the best average performance with a rise of 1.47%, while commodity ETFs had the worst performance with an average decline of 0.86% [8] - The top-performing ETFs today included Tianhong Innovative Drug ETF (517380.SH) with a gain of 4.36%, Fortune Innovative Drug ETF (159748.SZ) with a gain of 3.57%, and Guotai Innovative Drug ETF (159377.SZ) with a gain of 3.50% [10][11] - The trading volume of ETFs today was led by A500 ETF (512050.SH) with a transaction amount of 2.855 billion yuan, followed by A500 Index ETF (159351.SZ) with 2.747 billion yuan, and CSI 300 ETF (510300.SH) with 2.323 billion yuan [13]
多只创新药ETF大涨；债券ETF总规模突破3000亿元丨ETF晚报
2 1 Shi Ji Jing Ji Bao Dao·2025-06-09 10:07